<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753051</url>
  </required_header>
  <id_info>
    <org_study_id>HE501122</org_study_id>
    <nct_id>NCT00753051</nct_id>
  </id_info>
  <brief_title>Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)</brief_title>
  <acronym>TCRS</acronym>
  <official_title>Treatment of Clozapine-resistant Schizophrenia : Comparison Between Augmentation With Haloperidol and Electroconvulsive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clozapine treatment resistant schizophrenia is still prevalent.The effectiveness of
      augmenting clozapine : one augmenting with haloperidol and the other with electroconvulsive
      therapy should be determined.This study is a randomized control trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS , HAM-D , CGI , AIMS Scores</measure>
    <time_frame>every 4 weeks for 24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clozapine as the main agent and it will be adjuncted by haloperidol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clozapine as the main agent and it will be adjuncted by electroconvulsive therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clozapine+haloperidol</intervention_name>
    <description>clozapine 300-900 mg/d haloperidol 4-60 mg/d</description>
    <arm_group_label>1.</arm_group_label>
    <other_name>clopaze, haloperidol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clozapine,electroconvulsive therapy</intervention_name>
    <description>clozapine 300-900 mg/d electroconvulsive therapy 4-12 times</description>
    <arm_group_label>2.</arm_group_label>
    <other_name>clopaze , Thymatron ECT machine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. schizophrenic patients diagnosed with schedules for clinical assessment in
             neuropsychiatry ( SCAN )in accordance with DSM-IV-TR or ICD-10

          2. Resistant to at least 6 weeks of clozapine treatment in therapeutic dosage

          3. Voluntary to participate the research protocol expressed by signing informed consent
             form

        Exclusion Criteria:

          1. Patient does not volunteer himself or herself

          2. Patient is having epilepsy, DM, cardiac disease, autistic disorder and illiterate

          3. Patient is deaf, blind , dumb to obstruct good communication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchat Paholpak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry.Faculty of Medicine.Khon Kaen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry.Faculty of Medicine.KhonKaen University.</name>
      <address>
        <city>Muang</city>
        <state>KhonKaen</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Suchat Paholpak</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>clozapine-resistant schizophrenics</keyword>
  <keyword>haloperidol augmenting clozapine</keyword>
  <keyword>electroconvulsive therapy augmenting clozapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Clozapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

